Literature DB >> 18680204

Alpha2-agonists as analgesic agents.

Maria Paola Giovannoni1, Carla Ghelardini, Claudia Vergelli, Vittorio Dal Piaz.   

Abstract

It is well known that norepinephrine is involved in the control of pain by modulating pain-related responses through various pathways. alpha(2)-Adrenergic agonists have a well-established analgesic profile and, in the recent years, have found a wider application, in particular as adjunct to anesthetics and analgesics in perioperative settings. This review analyzes the alpha(2)-agonists currently in clinical use, starting from the prototype Clonidine, as well as the most promising and studied molecules. In addition, an overview of the imidazoles, imidazolines, and hydroxyethyl-thioureas derivatives published in both the open and patented literature is presented, providing chemical description and pharmacological data. Finally, the most commonly alpha(2)-agonists used in veterinary medicine are described. (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18680204     DOI: 10.1002/med.20134

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  11 in total

Review 1.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

2.  The Neurotoxin DSP-4 Induces Hyperalgesia in Rats that is Accompanied by Spinal Oxidative Stress and Cytokine Production.

Authors:  Jillienne C Touchette; Joshua W Little; Gerald H Wilken; Daniela Salvemini; Heather Macarthur
Journal:  Neuroscience       Date:  2018-02-05       Impact factor: 3.590

3.  Presynaptic inhibition of transient receptor potential vanilloid type 1 (TRPV1) receptors by noradrenaline in nociceptive neurons.

Authors:  Saikat Chakraborty; Vincent Elvezio; Martin Kaczocha; Mario Rebecchi; Michelino Puopolo
Journal:  J Physiol       Date:  2017-02-22       Impact factor: 5.182

4.  Monoamines and neuropeptides interact to inhibit aversive behaviour in Caenorhabditis elegans.

Authors:  Holly Mills; Rachel Wragg; Vera Hapiak; Michelle Castelletto; Jeffrey Zahratka; Gareth Harris; Philip Summers; Amanda Korchnak; Wenjing Law; Bruce Bamber; Richard Komuniecki
Journal:  EMBO J       Date:  2011-11-29       Impact factor: 11.598

Review 5.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

6.  Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.

Authors:  M G Cascio; L A Gauson; L A Stevenson; R A Ross; R G Pertwee
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

7.  Activation of the α2B adrenoceptor by the sedative sympatholytic dexmedetomidine.

Authors:  Daopeng Yuan; Zhongmin Liu; Jonas Kaindl; Shoji Maeda; Jiawei Zhao; Xiaoou Sun; Jun Xu; Peter Gmeiner; Hong-Wei Wang; Brian K Kobilka
Journal:  Nat Chem Biol       Date:  2020-03-09       Impact factor: 15.040

8.  Intrathecal administration of clonidine or yohimbine decreases the nociceptive behavior caused by formalin injection in the marsh terrapin (Pelomedusa subrufa).

Authors:  Christopher M Makau; Philemon K Towett; Klas S P Abelson; Titus I Kanui
Journal:  Brain Behav       Date:  2014-10-02       Impact factor: 2.708

9.  Morphine and clonidine combination therapy improves therapeutic window in mice: synergy in antinociceptive but not in sedative or cardiovascular effects.

Authors:  Laura S Stone; Jonathan P German; Kelly F Kitto; Carolyn A Fairbanks; George L Wilcox
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

10.  Effects of a Short Course of Oral Prednisolone in Patients with Bladder Pain Syndrome with Fluctuating, Worsening Pain despite Low-Dose Triple Therapy.

Authors:  Hee Jong Jeong
Journal:  Int Neurourol J       Date:  2012-12-31       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.